Paper Details

  1. Home
  2. Paper Details

In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.

Author: BorowiakArleta, BłońskiJerzy Z, Cebula-ObrzutBarbara, KiliańskaZofia M, KotkowskaAleksandra, RobakTadeusz, RogalińskaMałgorzata, SmolewskiPiotr, WawrzyniakEwa, ŻołnierczykJolanta D

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Chronic lymphocytic leukemia (CLL) is a type of cancer with varied characteristics due to differences in how cells regulate their life cycle and death. A key goal of CLL treatment is to overcome resistance to cell death and trigger this process in cancerous cells.
Paper Details　
Original Abstract of the Article :
The heterogeneity of chronic lymphocytic leukemia (CLL) is thought to be due to differences in the expression of factors that regulate apoptosis and cell cycle, giving rise to diverse apoptotic disturbances and tumor properties. Therefore, the primary goal in CLL treatment is to overcome resistance ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s1734-1140(13)71022-3

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: A Heterogeneous Desert

Chronic lymphocytic leukemia (CLL) is a complex and heterogeneous desert, a vast landscape with diverse cell populations. These cells exhibit varying responses to treatment, adding complexity to the fight against this disease. This study explores the challenge of overcoming resistance to apoptosis, a key obstacle in CLL treatment. The researchers investigated the response of CLL cells to various combinations of purine analogs and alkylating agents, hoping to find a winning strategy in this intricate battle. They found that the heterogeneity of CLL cells presents a significant hurdle, making a one-size-fits-all approach ineffective. The researchers are using a combination of approaches, a strategic alliance in this challenging environment, to combat this disease.

Navigating the Heterogeneity of CLL

The diverse nature of CLL cells presents a complex challenge for treatment. It's like navigating a desert with ever-shifting sands, where each dune presents a new obstacle. This study highlights the need for personalized approaches, tailoring treatments to the specific characteristics of each patient's CLL cells.

Hope in the Desert: Personalized Approaches

The quest for effective CLL treatments is an ongoing expedition. Researchers are exploring new combinations of drugs and personalized approaches, seeking a path through this complex desert. The goal is to find a strategy that effectively targets the diverse CLL cells, allowing for more targeted and effective therapies.

Dr.Camel's Conclusion

CLL is a complex desert, and the quest for effective treatments is an ongoing journey. By understanding the heterogeneity of CLL cells and exploring personalized approaches, we can hope to find a path through this challenging terrain, offering a beacon of hope for patients facing this disease.

Date :
  1. Date Completed 2014-02-07
  2. Date Revised 2020-01-06
Further Info :

Pubmed ID

23744431

DOI: Digital Object Identifier

10.1016/s1734-1140(13)71022-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.